SequelSEC

ORAGENICS INC OGEN

Pharmaceutical Preparations · CIK 0001174940 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$37.65K
Fiscal year ended 2023-12-31
Operating income
-$20.90M
Fiscal year ended 2023-12-31
Free cash flow
Unavailable
Fiscal year ended 2023-12-31

Valuation, from the filing

Public float$3.13MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.72Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
R&D / revenue41140.4%97th
Operating margin-55519.9%4th
Net margin-54858.1%4th
SBC / revenue2700.5%94th
Revenue YoY growth-71.4%18th

ORAGENICS INC (OGEN) reported revenue of $37.65K and net income of -$20.66M for the fiscal year ended 2023-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ORAGENICS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ORAGENICS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Revenue$37.65K
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$20.90M
Net income-$20.66M
Research & development$15.49M
Weighted-average diluted sharesUnavailable
Pretax income-$20.66M
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$5.45M
Selling & marketingUnavailable

Balance

ORAGENICS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Cash & equivalents$3.48M
Total assets$4.97M
Current assets$3.87M
Total liabilities$1.80M
Current liabilities$1.80M
Total equity incl. NCI$3.17M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

ORAGENICS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Operating cash flow-$7.29M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$283.88K
Net change in cash-$7.94M
Stock-based compensation$892.89K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$27.39K

Derived

ORAGENICS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-55519.9%
FCF marginUnavailable
SBC / revenue2371.4%
Current ratio2.15x
Revenue YoY growth-71.4%
Net margin-54858.1%
R&D / revenue41140.4%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open OGEN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.